Published in J Immunol on May 15, 1993
Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci U S A (1999) 6.05
Cytokine therapeutics: lessons from interferon alpha. Proc Natl Acad Sci U S A (1994) 2.90
Innate and adaptive interferons suppress IL-1α and IL-1β production by distinct pulmonary myeloid subsets during Mycobacterium tuberculosis infection. Immunity (2011) 2.19
Synergistic benefit in inflammatory arthritis by targeting I kappaB kinase epsilon and interferon beta. Ann Rheum Dis (2008) 1.82
Histone deacetylase inhibitors for treating a spectrum of diseases not related to cancer. Mol Med (2011) 1.41
A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis. Gut (2003) 1.19
Recombinant interferon-alpha selectively inhibits the production of interleukin-5 by human CD4+ T cells. J Clin Invest (1996) 1.04
Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies. Rheumatology (Oxford) (2015) 1.01
Interferon-alpha induces interleukin-18 binding protein in chronic hepatitis C patients. Clin Exp Immunol (2002) 0.93
Interferon type I receptor-deficient mice have altered disease symptoms in response to influenza virus. Brain Behav Immun (2006) 0.90
Applications and limitations of inflammatory biomarkers for studies on neurocognitive impairment in HIV infection. J Neuroimmune Pharmacol (2013) 0.88
Clash of the Cytokine Titans: counter-regulation of interleukin-1 and type I interferon-mediated inflammatory responses. Cell Mol Immunol (2016) 0.83
Acute and chronic immune biomarker changes during interferon/ribavirin treatment in HIV/HCV co-infected patients. J Viral Hepat (2014) 0.78
Interleukin-1. Rev Infect Dis (1984) 11.24
Induction by IL 1 and interferon-gamma: tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1). J Immunol (1986) 10.92
Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. J Exp Med (1986) 10.91
Nucleotide sequence of human monocyte interleukin 1 precursor cDNA. Proc Natl Acad Sci U S A (1984) 8.84
Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med (1988) 7.96
Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line. Science (1987) 7.22
High-resolution record of Northern Hemisphere climate extending into the last interglacial period. Nature (2004) 6.44
Growth of a cloned helper T cell line induced by a monoclonal antibody specific for the antigen receptor: interleukin 1 is required for the expression of receptors for interleukin 2. J Immunol (1984) 5.51
Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. J Clin Invest (1988) 5.22
Interleukin-1 and the pathogenesis of the acute-phase response. N Engl J Med (1984) 5.12
Calcium inward currents in internally perfused giant axons. J Physiol (1973) 5.02
Purification and some characteristics of human T-cell growth factor from phytohemagglutinin-stimulated lymphocyte-conditioned media. Proc Natl Acad Sci U S A (1980) 4.91
Immunoregulatory feedback between interleukin-1 and glucocorticoid hormones. Science (1986) 4.25
[Effect of tetrodotoxin and tertaethylammonium chloride on the inside of the membrane of Ranvier's node in Xenopus laevis]. Pflugers Arch (1969) 3.88
Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood (1994) 3.74
Interleukin 1 induces interleukin 1. I. Induction of circulating interleukin 1 in rabbits in vivo and in human mononuclear cells in vitro. J Immunol (1987) 3.61
Interleukin-18 (IFNgamma-inducing factor) induces IL-8 and IL-1beta via TNFalpha production from non-CD14+ human blood mononuclear cells. J Clin Invest (1998) 3.54
Stimulation of muscle protein degradation and prostaglandin E2 release by leukocytic pyrogen (interleukin-1). A mechanism for the increased degradation of muscle proteins during fever. N Engl J Med (1983) 3.49
Serum levels of cytokines in chronic liver diseases. Gastroenterology (1992) 3.47
Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response. Immunity (1999) 3.43
Human recombinant interleukin 1 stimulates collagenase and prostaglandin E2 production by human synovial cells. J Clin Invest (1986) 3.43
Endotoxin and tumor necrosis factor induce interleukin-1 gene expression in adult human vascular endothelial cells. Am J Pathol (1986) 3.35
Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma. J Exp Med (1984) 3.31
Human cutaneous T cell lymphoma and leukemia cell lines produce and respond to T cell growth factor. J Exp Med (1981) 3.30
Ability of human leukocytic pyrogen to enhance phytohemagglutinin induced murine thymocyte proliferation. Cell Immunol (1981) 3.22
IL-1 beta -converting enzyme (caspase-1) in intestinal inflammation. Proc Natl Acad Sci U S A (2001) 3.21
Human leukocytic pyrogen: purification and development of a radioimmunoassay. Proc Natl Acad Sci U S A (1977) 3.15
A European evidence-based guideline for the prevention of type 2 diabetes. Horm Metab Res (2010) 3.15
Inflammatory markers and the risk of Alzheimer disease: the Framingham Study. Neurology (2007) 3.12
Cachectin/tumor necrosis factor regulates hepatic acute-phase gene expression. J Clin Invest (1986) 3.05
Demonstration and characterization of two distinct human leukocytic pyrogens. J Exp Med (1974) 2.98
An update on human interleukin-1: from molecular biology to clinical relevance. J Clin Immunol (1985) 2.90
T-cell lines established from human T-lymphocytic neoplasias by direct response to T-cell growth factor. Proc Natl Acad Sci U S A (1980) 2.89
Cachectin/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodeling. Science (1988) 2.87
Interleukin 1 (IL-1) gene expression, synthesis, and effect of specific IL-1 receptor blockade in rabbit immune complex colitis. J Clin Invest (1990) 2.86
Pretranslational modulation of acute phase hepatic protein synthesis by murine recombinant interleukin 1 (IL-1) and purified human IL-1. J Exp Med (1985) 2.84
Impaired IL-18 processing protects caspase-1-deficient mice from ischemic acute renal failure. J Clin Invest (2001) 2.84
Cytotoxicity of human pI 7 interleukin-1 for pancreatic islets of Langerhans. Science (1986) 2.83
Induced micronucleus frequencies in peripheral lymphocytes as a screening test for carriers of a BRCA1 mutation in breast cancer families. Cancer Res (2000) 2.83
Interleukin 1 stimulates fibroblasts to produce granulocyte-macrophage colony-stimulating activity and prostaglandin E2. J Clin Invest (1986) 2.82
Chronic infections and the risk of carotid atherosclerosis: prospective results from a large population study. Circulation (2001) 2.82
Interleukin-18 and interleukin-1 beta: two cytokine substrates for ICE (caspase-1). J Clin Immunol (1999) 2.79
Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat Immunol (2001) 2.79
Lymphokines. N Engl J Med (1987) 2.77
Isolation of an interleukin-1-like factor from human joint effusions. Arthritis Rheum (1983) 2.75
Molecular basis of fever in humans. Am J Med (1982) 2.69
Duodenal metal-transporter (DMT-1, NRAMP-2) expression in patients with hereditary haemochromatosis. Lancet (1999) 2.68
Prostaglandins posttranscriptionally inhibit monocyte expression of interleukin 1 activity by increasing intracellular cyclic adenosine monophosphate. J Immunol (1986) 2.68
Mammalian Grb2 regulates multiple steps in embryonic development and malignant transformation. Cell (1998) 2.64
Adherent cell function in murine T-lymphocyte antigen recognition. IV. Enhancement of murine T-cell antigen recognition by human leukocytic pyrogen. J Exp Med (1979) 2.64
Tumor necrosis factor-alpha and interleukin-1beta synergistically depress human myocardial function. Crit Care Med (1999) 2.63
Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.2-43. Am J Hum Genet (1998) 2.59
Gene expression, synthesis, and secretion of interleukin 18 and interleukin 1beta are differentially regulated in human blood mononuclear cells and mouse spleen cells. Proc Natl Acad Sci U S A (1999) 2.57
A specific receptor antagonist for interleukin 1 prevents Escherichia coli-induced shock in rabbits. FASEB J (1991) 2.52
Long-term human cytolytic T-cell lines allospecific for HLA-DR6 antigen are OKT4+. Proc Natl Acad Sci U S A (1982) 2.51
The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays. Cancer Immunol Immunother (2007) 2.49
Human leukocytic pyrogen induces release of specific granule contents from human neutrophils. J Clin Invest (1978) 2.48
IL-1 induction-capacity of defined lipopolysaccharide partial structures. J Immunol (1989) 2.41
Acute toxoplasmosis leads to lethal overproduction of Th1 cytokines. J Immunol (2001) 2.41
Tumour necrosis factor production in Falciparum malaria and its association with schizont rupture. Clin Exp Immunol (1989) 2.41
Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis. Blood (2001) 2.40
IL-6 and APPs: anti-inflammatory and immunosuppressive mediators. Immunol Today (1997) 2.37
Enhancement of growth of virulent strains of Escherichia coli by interleukin-1. Science (1991) 2.37
Colchicine therapy for familial mediterranean fever. A double-blind trial. N Engl J Med (1974) 2.35
Chemotactic cytokines: the role of leukocytic pyrogen and epidermal cell thymocyte-activating factor in neutrophil chemotaxis. J Immunol (1984) 2.34
Induction of human interleukin-1 by a product of Staphylococcus aureus associated with toxic shock syndrome. J Clin Invest (1984) 2.33
Acute inflammation and a Shwartzman-like reaction induced by interleukin-1 and tumor necrosis factor. Synergistic action of the cytokines in the induction of inflammation and microvascular injury. Am J Pathol (1987) 2.27
A randomized, controlled study to assess the conversion from calcineurin-inhibitors to everolimus after liver transplantation--PROTECT. Am J Transplant (2012) 2.24
The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J Viral Hepat (2014) 2.23
A low dose of recombinant interleukin 1 protects granulocytopenic mice from lethal gram-negative infection. Proc Natl Acad Sci U S A (1988) 2.22
Interleukin-1 immunoreactive innervation of the human hypothalamus. Science (1988) 2.22
Inducible interleukin-1 gene expression in human vascular smooth muscle cells. J Clin Invest (1986) 2.21
Role of arachidonate metabolism in the immunoregulatory function of human leukocytic pyrogen/lymphocyte-activating factor/interleukin 1. J Immunol (1983) 2.20
Staphylococcus epidermidis induces complement activation, tumor necrosis factor and interleukin-1, a shock-like state and tissue injury in rabbits without endotoxemia. Comparison to Escherichia coli. J Clin Invest (1991) 2.17
Multiple biological activities of human recombinant interleukin 1. J Clin Invest (1986) 2.16
Neutralization of interleukin-18 reduces severity in murine colitis and intestinal IFN-gamma and TNF-alpha production. Am J Physiol Regul Integr Comp Physiol (2001) 2.16
Leptin-deficient (ob/ob) mice are protected from T cell-mediated hepatotoxicity: role of tumor necrosis factor alpha and IL-18. Proc Natl Acad Sci U S A (2000) 2.14
The events of primary T cell activation can be staged by use of Sepharose-bound anti-T3 (64.1) monoclonal antibody and purified interleukin 1. J Immunol (1985) 2.14
Response to local inflammation of IL-1 beta-converting enzyme- deficient mice. J Immunol (1997) 2.10
The IL-1 receptor/toll-like receptor superfamily: crucial receptors for inflammation and host defense. Immunol Today (2000) 2.09
Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost (2006) 2.08
Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res (1997) 2.08
Balance of synovial fluid IL-1 beta and IL-1 receptor antagonist and recovery from Lyme arthritis. Lancet (1993) 2.05
The effects of interleukin 1 on human B cell activation and proliferation. J Immunol (1983) 2.05
Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. Cancer Res (1998) 2.04
Structural requirements of six naturally occurring isoforms of the IL-18 binding protein to inhibit IL-18. Proc Natl Acad Sci U S A (2000) 2.03
Rheumatoid cachexia: cytokine-driven hypermetabolism accompanying reduced body cell mass in chronic inflammation. J Clin Invest (1994) 2.01
Mitotic stability of fragile X mutations in differentiated cells indicates early post-conceptional trinucleotide repeat expansion. Nat Genet (1993) 2.00
Ability of human leukocytic pyrogen to stimulate brain prostaglandin synthesis in vitro. J Neurochem (1981) 1.99
Take action to prevent diabetes--the IMAGE toolkit for the prevention of type 2 diabetes in Europe. Horm Metab Res (2010) 1.99
Tumor necrosis factor and endotoxin induce similar metabolic responses in human beings. Surgery (1988) 1.98
Potassium inactivation in single myelinated nerve fibres of Xenopus laevis. Pflugers Arch (1971) 1.98
Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth. J Biol Chem (2000) 1.97